Mei Ri Jing Ji Xin Wen·2025-05-22 00:17Group 1 - Heng Rui Pharmaceutical has set the final price for its H-share issuance at HKD 44.05 per share, which is the upper limit of the previously expected price range [1] - The H-shares will officially be listed on the Hong Kong Stock Exchange on May 23, with cornerstone investors including GIC, Invesco, UBS Global Asset Management, Hillhouse Capital, and Boyu Capital [1] - The purpose of this H-share issuance is to further promote the company's global strategic layout, enhance its international brand image, and strengthen connections with overseas capital markets [1] Group 2 - Chao Hong Ji is planning to issue H-shares for listing on the Hong Kong Stock Exchange, with details and plans yet to be finalized [2] - The company has experienced significant stock price fluctuations, with a cumulative increase of over 20% in closing prices over three consecutive trading days [2] - This move is aimed at expanding the international market and enhancing brand influence, which is expected to positively impact the company's long-term development [2] Group 3 - ZTO Express reported a revenue of CNY 10.892 billion for Q1 2025, representing a year-on-year increase of 9.4% [3] - The gross profit for the same period was CNY 2.689 billion, a decrease of 10.4% year-on-year, while the adjusted net profit was CNY 2.259 billion, up 1.6% year-on-year [3] - The company completed a total of 8.5 billion packages in Q1, marking a year-on-year growth of 19.1% [3] Group 4 - Hangpin Life Technology announced the acquisition of 1 million shares of China Petroleum at an average price of HKD 6.285 per share, totaling HKD 6.285 million [4] - This acquisition is part of the company's diversification strategy, aimed at increasing investment returns and financial flexibility [4] - The shares acquired will be held as a long-term investment to achieve capital appreciation and potential dividend income [4]